Author: Dino Mustafić

July 2, 2020 Off

Abivax starts testing ABX464 with older Covid-19 patients

By Dino Mustafić

Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.

July 2, 2020 Off

EUSA Pharma gets FDA’s green light for further testing of siltuximab in COVID-19 patients with acute respiratory distress syndrome

By Dino Mustafić

EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, received the approval from the U.S. Food & Drug Administration (FDA) for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to test intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).

June 29, 2020 Off

Adalvo waiting EC’s marketing authorization for Livogiva

By Dino Mustafić

Pharmaceutical company Adalvo today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Livogiva, indicated for use in postmenopausal women with osteoporosis who are at high risk of having bone fractures.